Fingerprint
Dive into the research topics of 'Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
The FOENIX-CCA2 Study Investigators, Lipika Goyal, Funda Meric-Bernstam, Gustave Villejuif, Juan W. Valle, Chigusa Morizane, Thomas B. Karasic, Thomas A. Abrams, Junji Furuse, Robin K. Kelley, Philippe A. Cassier, Heinz-josef Klümpen, Heung-moon Chang, Li-tzong Chen, Josep Tabernero, Do-youn Oh, Amit Mahipal, Markus Moehler, Edith P. Mitchell, Yoshito Komatsu
- Stanford University
- Stanford Health Care
- University of California, Irvine
- Dana-Farber Cancer Institute
- University of Texas MD Anderson Cancer Center
- Institut Gustave Roussy
- Centre Leon Berard
- University College London (UCL)
- National Cancer Center Hospital
- Kanagawa Cancer Center
- Hokkaido University
- Tohoku University
- Seoul National University
- Vall D'Hebron Institute of Oncology
- University of Vic Central Catalonia
- Hospital Quirón
- Institut de Cancerlogie Gustave Roussy
- The Christie Hospital NHS Foundation Trust
- Hospital of the University of Pennsylvania
- The Sidney Kimmel Cancer Center, Thomas Jefferson University
- VU University Medical Center
- University of Amsterdam
- University of Ulsan
- Asan Medical Center
- National Health Research Institutes
- Mayo Clinic (HQ)
- Johannes Gutenberg University
- Mayo Clinic
- Epstein Health
- Taiho Oncology Inc
- Ilumina
Research output: Contribution to journal › Article › peer-review
26
Downloads
(Pure)